Companies › Endeavor Biomedicines
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Respiratory.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Taladegib (ENV-101) Smoothened homolog antagonist | SMO | Phase 2 | Idiopathic Pulmonary Fibrosis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06422884 | Taladegib (ENV-101) | Phase 2 | Idiopathic Pulmonary Fibrosis | Respiratory | Oct 2026 |
| NCT07454291 | Taladegib (ENV-101) | Phase 1 | Idiopathic Pulmonary Fibrosis | Respiratory | Oct 2026 |
–
Expedition Therapeutics Dragonboat Biopharmaceutical Company Kinaset Therapeutics Melius Pharma Jianmin Pharmaceutical Group
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.